Prognostic value of serum soluble ST2 in stable coronary artery disease: a prospective observational study - PubMed (original) (raw)

Observational Study

Prognostic value of serum soluble ST2 in stable coronary artery disease: a prospective observational study

Hack-Lyoung Kim et al. Sci Rep. 2021.

Abstract

The role of ST2 in stable coronary artery disease (CAD) has not yet been well defined. This study was performed to investigate baseline serum soluble ST2 (sST2) level can predict clinical outcomes in patients with stable CAD. A total of 388 consecutive patients with suspected CAD (65 years and 63.7% male) in stable condition referred for elective invasive coronary angiography (ICA) was prospectively recruited. Major adverse cardiovascular event (MACE), including cardiac death, non-fatal myocardial infarction, coronary revascularization (90 days after ICA), and ischemic stroke during clinical follow-up was assessed. Most of the patients (88.0%) had significant CAD (stenosis ≥ 50%). During median follow-up of 834 days, there was 29 case of MACE (7.5%). The serum sST2 level was significantly higher in patients with MACE than those without (47.3 versus 30.6 ng/ml, P < 0.001). In multiple Cox regression model, higher sST2 level (≥ 26.8 ng/ml) was an independent predictor of MACE even after controlling potential confounders (hazard ratio, 13.7; 95% confidence interval 1.80-104.60; P = 0.011). The elevated level of baseline sST2 is associated with an increased risk of adverse clinical events in stable CAD patients. Studies with larger sample size are needed to confirm our findings.

© 2021. The Author(s).

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1

Figure 1

Soluble ST2 levels in patients with and without events. MACE major adverse cardiac event.

Figure 2

Figure 2

Receiver operating curve analysis showing cutoff value of soluble ST predicting major adverse cardiac event.

Figure 3

Figure 3

Event free survival rate according to soluble ST2 value.

References

    1. Lozano R, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010. Lancet. 2010;380:2095–2098. doi: 10.1016/S0140-6736(12)61728-0. -DOI -PMC -PubMed
    1. Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur. Heart J. 2006;27:1610–1609. doi: 10.1093/eurheartj/ehi733. -DOI -PubMed
    1. Morrow DA, et al. National academy of clinical biochemistry laboratory medicine practice guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115:e356–e375. doi: 10.1161/CIRCULATIONAHA.106.683110. -DOI -PubMed
    1. Weinberg EO, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106:2961–2966. doi: 10.1161/01.CIR.0000038705.69871.D9. -DOI -PMC -PubMed
    1. Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am. J. Cardiol. 2011;107:259–267. doi: 10.1016/j.amjcard.2010.09.011. -DOI -PMC -PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources